FDA Clears Path for SODIUM FLUORIDE F 18 Injection Re-approval Process

Summary

The US Food and Drug Administration (FDA) has concluded that SODIUM FLUORIDE F 18 injection, a medical product, was not withdrawn from the market due to safety or efficacy concerns. This decision enables the FDA to potentially approve abbreviated new drug applications (ANDAs) for this product, pending compliance with all applicable regulations.